In 2009, Patrick Phelps joined a group of scientists, physicians, and other industry professionals to form a company to make PET scan more broadly available to researchers, clinicians, and drug developers through new generations of molecular imaging diagnostics and devices. His strong commercial background within the molecular imaging industry is a perfect match to build Sofie Biosciences and lead innovative technology developments as President & CEO. He was promoted from Director of Business Development at Sofie where he was responsible for bringing to market new products, identifying new business opportunities, developing strategic alliances, marketing and sales. Prior to joining the Company, he served at Siemens Healthcare as part of a talented team who built the preclinical molecular imaging division where he drove the adoption of two generations of small animal PET, CT and SPECT imaging systems into the life science and pharmaceutical marketplaces. During his time at Siemens Molecular Imaging, he was responsible for sales, business development, product management and marketing.

In 2006, Siemens acquired CTI Molecular Imaging to become the market leader in molecular imaging. At the time, Mr. Phelps served as a Global Sales Support Manager for CTI Molecular Imaging where he was tasked with growing and supporting a worldwide sales organization with clinical medical imaging systems.  Early on in his career he joined a product management team at CTI Molecular Imaging who drove the paradigm shift into clinical hybrid imaging (eg. PET-CT), which now accounts for nearly all sales of PET and SPECT scanners. Currently Mr. Phelps is developing business strategies, assessing market opportunities, building operations and driving value creation as Sofie Biosciences moves into its next stage of growth and value creation. He holds a degree in Biology from the University of Colorado.